Summary of Genmab FY Conference Call - March 11, 2026 Company Overview - **Company**: Genmab (NasdaqGS: GMAB) - **Key Focus**: Late-stage pipeline products including EPKINLY, Rina-S, and petosemtamab Key Points Industry and Pipeline Developments - **2026 Significance**: A pivotal year for Genmab with multiple important readouts expected from its late-stage pipeline [2][3] - **FDA Breakthrough Therapy Designation**: All three key products (EPKINLY, Rina-S, petosemtamab) have received this designation, enhancing their development prospects [2] EPKINLY - **Upcoming Readouts**: - Potential full approval for refractory DLBCL in the first half of 2026 - Frontline DLBCL readout expected later in 2026 [4][10] - **Confidence in Trials**: High confidence in upcoming trials despite previous monotherapy trial not meeting overall survival endpoints due to confounding factors [5][6] - **Primary Endpoint**: Progression-Free Survival (PFS) is the primary endpoint for the upcoming trials, which is aligned with regulatory expectations [8] - **Commercial Potential**: If successful, EPKINLY could significantly expand its market, potentially reaching an additional 90,000 to 100,000 patients in frontline settings [13] Rina-S - **Key Study**: RAINFOL-01 study for second-line plus ovarian cancer is set to report in the second half of 2026 [22] - **Efficacy Data**: Previous data showed an overall response rate (ORR) exceeding 50%, with confidence in replicating this in upcoming trials [23] - **Market Opportunity**: Combined patient population for ovarian and endometrial cancer is approximately 120,000, with a favorable split [24] Petosemtamab - **Expected Data**: Anticipated readouts from one or two head and neck cancer trials in the second half of 2026 [30] - **Efficacy Metrics**: Previous data indicated a 63% overall response rate when combined with pembrolizumab, significantly higher than pembrolizumab monotherapy [32] - **Future Plans**: Plans to initiate a phase 3 trial in locally advanced head and neck cancer by the end of 2026 [33] Financial Outlook - **Peak Year Sales Estimates**: - EPKINLY: $3 billion+ - Rina-S: $2 billion+ - Petosemtamab: Multi-billion range [41] - **Growth Prospects**: Strong growth anticipated even after the loss of DARZALEX royalties, supported by a robust pipeline and ongoing clinical development plans [42] Operational Strategy - **Market Approach**: Genmab is building its own distribution network in key markets (U.S., Japan, Germany) while considering partnerships in other regions [38] - **Operational Efficiency**: The company is confident in managing operational expenses while scaling its business [39] Competitive Landscape - **Differentiation**: Rina-S is positioned as a potential best-in-class asset with a comprehensive clinical profile and ongoing trials across multiple indications [27][29] Additional Insights - **Thought Leader Feedback**: Positive feedback from thought leaders regarding EPKINLY's PFS data and its potential in combination therapies [7][18] - **Regulatory Engagement**: Ongoing discussions with regulators to ensure alignment on trial endpoints and data expectations [8] This summary encapsulates the critical insights and projections discussed during the Genmab FY conference call, highlighting the company's strategic focus on its late-stage pipeline and the anticipated impact on its market position and financial growth.